< Back

Compounded Semaglutide

MED-000012

Compounded semaglutide is a non-FDA-approved version of semaglutide prepared by compounding pharmacies. As of 2026, its legal availability is sharply restricted following the FDA's resolution of the semaglutide shortage in February 2025 — it is generally only available through narrow, documented clinical-need exceptions.

Medication Overview

Generic Name:

Medication Class:

Manufacturer:

Route:

Dosing Frequency:

Semaglutide

Compound

Compounding Pharmacy

Injection

Variable

Status:

Draft

Medication Summary

Aliases

Compounded Semaglutide

Search Keywords

compounded semaglutide

Medication Uses

Part of the DietApp.com GLP-1 Medication Database, a comprehensive, regularly reviewed reference covering every GLP-1-class medication.

Compounded semaglutide refers to versions of semaglutide prepared by a compounding pharmacy rather than manufactured by Novo Nordisk (maker of Ozempic® and Wegovy®). Compounded drugs are not FDA-approved — they don't undergo the FDA's premarket review for safety, effectiveness, or manufacturing quality.

Current legal status (2026): The FDA declared the semaglutide shortage resolved in February 2025, which ended the shortage-based exception that previously allowed widespread compounding. As of 2026, semaglutide is not on the FDA's drug shortage list or its 503B bulks list, meaning large-scale outsourcing facilities (503B) generally cannot legally compound it at all. Traditional compounding pharmacies (503A) can still compound semaglutide only for an individual patient with a documented, prescriber-certified clinical reason the FDA-approved product doesn't meet their needs — not simply for cost or convenience. On April 30, 2026, the FDA proposed formally removing semaglutide from the 503B bulks list entirely, which would close even more of the remaining pathway.

Dosage

Compounded semaglutide dosing varies by compounding pharmacy and is not standardized or FDA-reviewed the way Ozempic or Wegovy dosing is. This variability is itself a safety concern — see Warnings below.

Administration

Administration varies by product and compounding pharmacy. Because these products aren't FDA-reviewed, packaging, concentration labeling, and delivery devices (vials vs. pens) are not standardized across suppliers the way they are for approved semaglutide products.

Benefits

The active ingredient, when accurately compounded, is chemically the same as FDA-approved semaglutide. However, because compounded products aren't tested by the FDA for potency or purity, there's no independent verification that a given batch actually contains what it claims, at the concentration claimed.

Side Effects

Reported side effects are generally consistent with FDA-approved semaglutide (nausea, vomiting, diarrhea, injection-site reactions), but the FDA has also received over 455 adverse event reports specifically tied to compounded semaglutide, including dosing errors from patients self-administering incorrect doses from multidose vials — some requiring hospitalization.

Warnings

Compounded semaglutide has not been reviewed by the FDA for safety, effectiveness, or manufacturing quality. Documented risks include dosing errors from imprecise multidose vials, inconsistent purity and concentration between batches and suppliers, and counterfeit products entering the market through unlicensed online sellers. Eli Lilly and Novo Nordisk have pursued legal action against clinics misrepresenting compounded products as their branded medications. If you're considering compounded semaglutide, verify your pharmacy is a licensed 503A facility and that your prescriber has documented a genuine clinical reason for the compounded version rather than cost alone.

Drug Interactions

Interaction risks are expected to be similar to FDA-approved semaglutide (insulin, sulfonylureas, oral medication absorption), but since compounded formulations sometimes include added ingredients (such as B-vitamins or amino acids marketed as "personalized" blends), interaction and safety profiles cannot be assumed to match the approved product exactly.

Storage

Storage requirements vary by compounding pharmacy and are not standardized or FDA-verified. Follow your specific pharmacy's instructions exactly, and do not assume compounded product stability matches FDA-approved Ozempic or Wegovy.

References

FDA: Compounded GLP-1 Products enforcement updates (2025-2026)
Pharmacy Times: FDA Moves to Permanently Close the Door on Compounded GLP-1s
Harris Beach Murtha: GLP-1 Weight-Loss Drugs Off Shortage List

Last medically reviewed and updated: July 11, 2026.

Track Your Progress

Whatever form of semaglutide you're using, DietApp.com helps you track your dose, nutrition, weight, and symptoms in one place — useful context to bring to your provider regardless of your medication source.

Download DietApp.com

Related Resources

Semaglutide Medication Guide
Ozempic Medication Guide
Wegovy Medication Guide
GLP-1 Medication Library
Medication Safety Information

Is Compounded Semaglutide Legal? 2026 Status
Compounded vs. Brand-Name GLP-1s: What's the Real Difference?
What Is Semaglutide?
Frequently Asked Questions About GLP-1 Therapy

More From DietApp.com

Explore the full GLP-1 Tracker knowledge base on DietApp.com

Explore DietApp.com Tools

BMI Calculator — Get an instant estimate and see what it does (and doesn't) tell you about your health
GLP-1 Dose & Injection Tracker — Log your dose automatically
AI Food Recognition — Snap a photo of your meal for instant protein, fiber, and calorie tracking
Protein & Hydration Dashboard — See your daily totals at a glance
Symptom & Side Effect Log — Track patterns over time to bring to your next appointment
Download DietApp.com — Start tracking your GLP-1 journey today

About DietApp.com

DietApp.com combines evidence-based GLP-1 medication education with practical treatment tracking tools. This page is for general informational purposes and is not medical, legal, or purchasing advice. The information on DietApp.com should not replace professional medical advice, diagnosis, or treatment.